Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Both Alzheimer's disease and senile dementia of the Alzheimer type (AD/SDAT) are progressive dementias characterized neuropathologically by the presence in the cerebral cortex of numerous neurofibrillary tangles and neuritic plaques. We use the abbreviation AD/SDAT to denote all such cases, irrespective of age of onset. Studies of neurotransmitter-related parameters in autopsied brain tissues from patients with AD/SDAT have, to date, been confined to five putative transmitter systems. Acetycholine-releasing neurones seem to be most markedly and consistently affected, as judged by the extensive reductions in choline acetyltransferase (ChAT) and acetylcholinesterase activities that have been reported. Despite numerous studies, there is no consistent evidence for the involvement of neurones releasing dopamine, noradrenaline, serotonin, or gamma-aminobutyric acid in AD/SDAT, nor for loss of muscarinic cholinergic receptors. Thus, the involvement of cholinergic neurones in AD/SDAT seems to be specific. However, the possible involvement of neurones using other chemicals as transmitters has yet to be explored. The recent recognition of the existence of so-called 'peptidergic neurones' in the mammalian brain (for review see ref. 8) and the availability of radioimmunoassay (RIA) techniques for studying these peptides, have led us to begin a systematic investigation of neuropeptides in autopsied brain tissue from cases of AD/SDAT, and from neurologically normal individuals. We report here results obtained with a RIA for somatostatin, showing that somatostatin-like immunoreactivity in the cerebral cortex is reduced in tissue from AD/SDAT patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ not only affects intracellular vesicular trafficking but could also affect primary cilia function directly or indirectly via its cognate binding receptors such as LRP1 [15, 50, 75].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“In addition, SST administration has been shown to be effective in improving cognitive impairment in AD patients [12, 15].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Dysfunctional SOMs have been identified as a hallmark of AD, and loss of SOMs in the cortex is associated with AD pathologies [10, 15, 65].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Additionally, AD patients have a specific loss of somatostatin-positive interneurons in the cortex [94] and hippocampus [95].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [94]
Citations
Cites
Hökfelt, T., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,547
NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
Neurotransmitter-related enzymes in senile dementia of the alzheimer type
Davies, P. (1979) · Brain Research · doi:10.1016/0006-8993(79)90336-6 · Cited by 634
Self-citationThe Prevalence and Malignancy of Alzheimer Disease: A Major Killer
Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040001001 · Cited by 619
Self-citationDementia of the Alzheimer Type
Terry, R. D., & Davies, P. (1980) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.03.030180.000453 · Cited by 529
Self-citationPrevalence and Malignancy of Alzheimer Disease
Lijtmaer, H., Fuld, P. A., & Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040088017 · Cited by 517
Self-citationNEOCORTICAL CHOLINERGIC NEURONS IN ELDERLY PEOPLE
White, P., Goodhardt, M. J., Keet, J. P., Hiley, C. R., Carrasco, L. H., Williams, I. E. I., & Bowen, D. M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92114-6 · Cited by 489
Davies, P., & Verth, A. H. (1977) · Brain Research · doi:10.1016/0006-8993(77)90758-2 · Cited by 313
Self-citationRadioimmunoassay for GH-Release Inhibiting Hormone
Arimura, A., Sato, H., Coy, D. H., & Schally, A. V. (1975) · Experimental Biology and Medicine · doi:10.3181/00379727-148-38631 · Cited by 302
Research works printed but not linked: 1
- Wisniewski, H. M. & Terry, R. D. in Neurobiology of Aging (eds Terry, R. D. & Gershon, S.) 265–280 (Raven, New York, 1976).
Cited by
Items 601–700 of 889
Functional Amyloids and their Possible Influence on Alzheimer Disease
Lau, A., Bourkas, M. E. C., Lu, Y. Q. Q., Ostrowski, L., Weber‐Adrian, D., Figueiredo, C., Arshad, H., Shoaei, S. Z. S., Morrone, C. D., Matan‐Lithwick, S. A., et al. (2017) · Discoveries · doi:10.15190/d.2017.9 · Cited by 13
Designing Drugs for Optimal Nervous System Activity
Greig, N. H., Brossi, A. R., Pei, X., Ingram, D. K., & Soncrant, T. T. (1995) · Springer eBooks · doi:10.1007/978-1-4899-1054-7_25 · Cited by 13
Mufson, E. J., Sobreviela, T., & Kordower, J. H. (1997) · Handbook of chemical neuroanatomy · doi:10.1016/s0924-8196(97)80009-7 · Cited by 22
Cutler, N. R., & Sramek, J. J. (1998) · CNS Drugs · doi:10.2165/00023210-199810050-00005 · Cited by 14
Neurotransmitter specific alterations in dementing disorders: Insights from animal models
Coyle, J. T., Singer, H. S., McKinney, M., & Price, D. (1984) · Journal of Psychiatric Research · doi:10.1016/0022-3956(84)90037-2 · Cited by 14
Early Stages of Late Onset Alzheimer's Disease
Forssell, L. G., Sjökvist, B., Winblad, B. G., & Forssell, L. G. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb04876.x · Cited by 13
Kwentus, J., Hart, R. P., Lingon, N., Taylor, J., & Silverman, J. J. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90188-9 · Cited by 14
Co-localization of GABA and neuropeptides in the cerebral cortex
Wise, S. P. (1985) · Trends in Neurosciences · doi:10.1016/0166-2236(85)90044-x · Cited by 14
Katzman, R. (1986) · Trends in Neurosciences · doi:10.1016/0166-2236(86)90165-7 · Cited by 15
Self-citationSomatostatin and Its Physiology in Man in Health and Disease
Wass, J. A. H. (1982) · Elsevier eBooks · doi:10.1016/b978-0-12-093602-1.50015-3 · Cited by 13
Vo, T. T., Jung, W. B., Jin, T., Im, G. H., Lee, S., & Kim, S. (2025) · Nature Communications · doi:10.1038/s41467-025-61771-5 · Cited by 13
“For example, SST expression in the frontal cortex and hippocampus is reduced to 30% in AD patients compared to control subjects 103 .”
Water maze impairments after combined depletion of somatostatin and serotonin in the rat
Dyer, K., & Cain, D. P. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.03.029 · Cited by 12
Duron, E., Vidal, J., Grouselle, D., Gabelle, A., Lehmann, S., Pasquier, F., Bombois, S., Buée, L., Allinquant, B., Schraen‐Maschke, S., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00297 · Cited by 12
“SOM concentration and expression levels are decreased in the cortex and hippocampus of AD patients (Davies et al., 1980; Gahete et al., 2010) while NPY-positive neurons are reduced in AD hippocampus (Kowall and Beal, 1988).”
BackgroundSomatostatin Receptor-4 Agonists as Candidates for Treatment of Alzheimer’s Disease
Sandoval, K. E., Witt, K. A., Crider, A. M., & Kontoyianni, M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50012-x · Cited by 15
Wallace, W., & Haroutunian, V. H. (1993) · Behavioural Brain Research · doi:10.1016/0166-4328(93)90136-e · Cited by 12
Alterations of somatostatin and its modulation by levodopa in MPTP-treated mouse brain
Asanuma, M., Ogawa, N., Sora, Y. H., Pongdhana, K., Haba, K., & Mori, A. (1990) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(90)90027-k · Cited by 12
Chemical Anatomy of the Hypothalamus
Nilaver, G. (1986) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30944-7 · Cited by 13
The postnatal expression of acetylcholinesterase in somatostatin-positive cells of mouse hippocampus
Forloni, G., Blake, K., Hohmann, C. H., & Coyle, J. T. (1989) · Developmental Brain Research · doi:10.1016/0165-3806(89)90094-1 · Cited by 12
Neurotransmitter Deficits in Alzheimer's Disease: Criteria for Significance
GREENWALD, B. S., Mohs, R. C., & Davis, K. L. (1983) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1983.tb04877.x · Cited by 12
Clinical Evaluation of Compounds for the Treatment of Memory Dysfunction
Growdon, J. H., Corkin, S., & Huff, F. J. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb37606.x · Cited by 12
Reduced cortical choline acetyltransferase activity in Gerstmann-Sträussler syndrome
ROBITAILLE, Y., Wood, P. L., Etienne, P. E., Lal, S., Finlayson, M. H., Gauthier, S. G., & Nair, N. P. V. (1982) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(82)80144-9 · Cited by 12
Biological markers in mental disorders: Post-mortem studies
Rossor, M. N. (1984) · Journal of Psychiatric Research · doi:10.1016/0022-3956(84)90033-5 · Cited by 14
New Intrathecal Drugs in Alzheimer's Disease and Psychometric Testing
Wilson, R. S., & Martin, E. M. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb31825.x · Cited by 12
Pedigo, N. W., & Rice, M. A. (1992) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(92)90095-d · Cited by 12
Actions of Somatostatin on Rat Neocortical Neurons in vitro
Vidal, C., & Zieglgänsberger, W. (1989) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1989.tb00355.x · Cited by 12
Somatostatin slows Aβ plaque deposition in aged APPNL-F/NL-F mice by blocking Aβ aggregation
Williams, D., Yan, B. Q., Wang, H., Negm, L., Sackmann, C., Verkuyl, C. E., Rezai-Stevens, V., Eid, S., Vediya, N., Sato, C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-29559-z · Cited by 13
Nilsson, P., Sörgjerd, K. M., Kakiya, N., Sasaguri, H., Watamura, N., Johansson, L. E., Shimozawa, M., Tsubuki, S., Zhou, Z., Loera‐Valencia, R., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251392782 · Cited by 12
“Thus, it is possible that the decreased levels of SRIF observed in ageing mouse and human brains 12,16 and in AD brains 25 lead to decreased neprilysin levels.”
Effect of cortistatin on tau phosphorylation at Ser262 site
Rubio, A., Pérez, M., de Lecea, L., & Ávila, J. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21689 · Cited by 12
“Somatostatin concentration was shown to be decreased in the brain and cerebrospinal fluid (CSF) of Alzheimer’s disease patients (Davies et al., 1980; Bissette et al., 1998; Nilsson et al., 2001).”
BackgroundMaeda, N., Matsuoka, N., Yamazaki, M., Arakawa, H., Ohkubo, Y., & Yamaguchi, I. (1994) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.64.147 · Cited by 11
Alzheimer's Disease and Aluminum Toxicology
Corain, B., Bombi, G. G., Tapparo, A., Nicolini, M., Zatta, P. F., Perazzolo, M., & Favarato, M. (1990) · Environmental Health Perspectives · doi:10.1289/ehp.9089233 · Cited by 11
Caserta, M. T. (1994) · Molecular and Chemical Neuropathology · doi:10.1007/bf03160106 · Cited by 11
“There is considerable evidence pointing to the loss of somatostatin (SMST)- and neuropeptide Y (NPY)-containing neurons in the cortices of patients with AD (fleal et al., 1986a,b; Chan-Palay, 1987; Coyle et al., 1991; Davies et al., 1980, 1990; Ferrier et al., 1983; Hardy et al., 1985; Kowall and Beal, 1988; Nakamura…”
BackgroundJolkkonen, J., Soininen, H. S., & Riekkinen, P. J. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90424-2 · Cited by 11
Neurotransmitters in Old Age and Dementia
Carlsson, A. (1986) · Springer eBooks · doi:10.1007/978-3-642-70958-6_17 · Cited by 11
Gilles, C., Ryckaert, P., Mol, J. D., de Maertelaere, V., & Mendlewicz, J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90143-1 · Cited by 11
Scarth, B., Jhamandas, K. H., Boegman, R. J., Beninger, R. J., & Reynolds, J. N. (1989) · Experimental Neurology · doi:10.1016/0014-4886(89)90077-0 · Cited by 11
Smith, G. C., Griffith, K. R., Sicher, A. R., Brockway, D. F., Proctor, E. A., & Crowley, N. A. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.09.014 · Cited by 11
“In this case, alcohol consumption would significantly worsen AD E/I imbalance as there is already a significant loss in a subtype of non-pyramidal somatostatin expressing neurons (Davies et al., 1980; Burgos-Ramos et al., 2008).”
BackgroundPaik, S., Somvanshi, R. K., Oliveira, H. A., Zou, S., & Kumar, U. (2021) · Biomedicines · doi:10.3390/biomedicines9010027 · Cited by 12
Somatostatin, an In Vivo Binder to Aβ Oligomers, Binds to βPFO Aβ(1–42) Tetramers
Puig, E., Tolchard, J. L., Riéra, A., & Carulla, N. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00470 · Cited by 10
Biochemical evidence for somatostatin receptors in murine neuroblastoma clone N1E-115
McKinney, M., & Barrett, R. W. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90330-0 · Cited by 10
Dysken, M. W., Falk, A., Pew, B., Kuskowski, M. A., & Krahn, D. D. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90631-b · Cited by 10
Chapter 19. Peptides of the Hypothalamus
Spatola, A. F. (1981) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61286-5 · Cited by 10
Niigawa, H., Tanimukai, S., Takeda, M., Hariguchi, S., & Nishimura, T. (1995) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)00113-v · Cited by 10
Iritani, S., & Satoh, K. (1991) · Synapse · doi:10.1002/syn.890090108 · Cited by 10
Reduced somatostatin-like immunoreactivity in the brain of dogs with an Eck fistula
Tateishi, K., Sato, S., Kato, A., Suzuki, K., Miura, Y., & Matsuoka, Y. (1987) · Regulatory Peptides · doi:10.1016/0167-0115(87)90185-6 · Cited by 10
Somatostatin and Behavior: Preclinical and Clinical Studies
Nemeroff, C. B., Walsh, T. J., & Bissette, G. (1987) · Springer eBooks · doi:10.1007/978-1-4684-5326-3_15 · Cited by 10
Frailes, M. T. D. L., Cacicedo, L., Lorenzo, M. J. V., Tolón, R. M., Fernández, G., & Franco, F. S. (1993) · Journal of Endocrinological Investigation · doi:10.1007/bf03348905 · Cited by 10
Immunopharmacological approach to the study of chronic brain disorders
Singh, V. K., & Fudenberg, H. H. (1986) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-9311-4_10 · Cited by 12
Shao, M., Botvinov, J., Banerjee, D., Girirajan, S., & Lüscher, B. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02832-x · Cited by 11
Metzendorf, N. G., Godec, A., Petrovic, A., Chourlia, A., Napoleone, A., Syvänen, S., Rofo, F., & Hultqvist, G. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118325 · Cited by 9
Strell, P., Johnson, S. T., Carchi, C., & Low, W. C. (2023) · Cell Transplantation · doi:10.1177/09636897231164712 · Cited by 11
Press‐Sandler, O., & Miller, Y. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00535 · Cited by 9
Masson, H., Popescu, I., Strubel, D., Cramer, H., & Kuntzmann, F. (1990) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1990.tb01591.x · Cited by 9
Arif, M., Ahmed, M. M., Kumabe, Y., Hoshino, H., Chikuma, T., & Kato, T. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.01.016 · Cited by 9
Neumann, W. L., Sandoval, K. E., Mobayen, S., Minaeian, M., Kukielski, S. G., Srabony, K. N., Frare, R., Slater, O., Farr, S. A., Niehoff, M. L., et al. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00044f · Cited by 9
Alanyl-Aminopeptidase Activity Decrease in Cerebrospinal Fluid of Alzheimer Patients
Iribar, M. C., Montes, J., Maldonado, R., & Peinado, J. M. (1997) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017021 · Cited by 9
Regulation of the preprosomatostatin gene by cyclic-AMP in cerebrocortical neurons
Capone, G. T., Choi, C., & Vertifuille, J. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00195-8 · Cited by 11
Somatostatin receptors in the senescent rat brain: a quantitative autoradiographic study
Sato, H., Ota, Z., & Ogawa, N. (1991) · Regulatory Peptides · doi:10.1016/0167-0115(91)90204-t · Cited by 9
Optimizing Drugs for Brain Action
Greig, N. H., Yu, Q., Utsuki, T., Holloway, H. W., Zhu, X., Perry, T., Lee, B. H., Ingram, D. K., & Lahiri, D. K. (2001) · Springer eBooks · doi:10.1007/978-1-4615-0579-2_24 · Cited by 9
Somatostatin and behaviour: The need for genetically engineered models
Viollet, C., Videau, C., & Epelbaum, J. (2000) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(00)00202-3 · Cited by 9
Shibata, S., Koga, Y., Hamada, T., & Watanabe, S. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90114-w · Cited by 9
Rational drug treatment of dementia?
Byrne, J., & Arie, T. (1985) · BMJ · doi:10.1136/bmj.290.6485.1845 · Cited by 9
Tsuchiyama, M., Kubota, Y., Sugita, M., Usuda, S., Yamano, M., & Tohyama, M. (1989) · Brain Research · doi:10.1016/0006-8993(89)90158-3 · Cited by 9
Trace Elements in Dementing Disorders
Markesbery, W. R., & Ehmann, W. D. (1988) · Elsevier eBooks · doi:10.1016/b978-0-12-506455-2.50020-4 · Cited by 9
AF64A-induced brain damage and its relation to dementia
Hörtnagl, H. (1994) · Springer eBooks · doi:10.1007/978-3-7091-9350-1_19 · Cited by 13
Clinical, Pathological and Biochemical Aspects of Alzheimer’s Disease
Wísniewski, H. M. (1986) · Advances in behavioral biology · doi:10.1007/978-1-4613-2179-8_4 · Cited by 9
Lee, S. H., Bolshakov, V. Y., & Shen, J. (2021) · Molecular Brain · doi:10.1186/s13041-021-00796-5 · Cited by 8
Chapter 25 Neuronal responses to injury and aging: lessons from animal models
Price, D. L., Koo, E. H., Sisodia, S. S., Martin, L. J., Koliatsos, V. E., Muma, N. A., Walker, L. C., & Cork, L. C. (1990) · Progress in brain research · doi:10.1016/s0079-6123(08)63186-6 · Cited by 10
Doraiswamy, P. M., Ranga, K., Krishnan, R. R., & Nemeroff, C. B. (1991) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80097-7 · Cited by 11
CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease.
Poewe, W. H., Benke, T., Karamat, E., Schelosky, L. D., Wagner, M., & Sperk, G. (1990) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.53.12.1105-a · Cited by 8
Alzheimer's disease and somatostatin: A therapeutic hypothesis
Vécsei, L. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90039-g · Cited by 8
In Vitro Cell Cultures as a Model of the Basal Forebrain
Wainer, B. H., Lee, H. J., Roback, J. D., & Hammond, D. N. (1991) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-0145-6_24 · Cited by 9
Nag, S., Yee, B. K., & Tang, F. M. K. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07911.x · Cited by 8
“We investigated the effects of intracerebroventricular infusion of Aβ (1-40) on memory; choline acetyltransferase (ChAT) activity; and somatostatin (SRIF), neuropeptide Y (NPY), and substance P (SP) levels in the cerebral cortex and hippocampus of male Sprague-Dawley rats weighing ∼250–300 grams.”
BackgroundMethodA role for somatostatin in the control of hamster growth
Borer, K. T., Shapiro, B., & Vinik, A. I. (1983) · Brain Research Bulletin · doi:10.1016/0361-9230(83)90009-6 · Cited by 9
Cholinergic systems and alzheimer's disease
DeFeudis, F. V. (1988) · Drug Development Research · doi:10.1002/ddr.430140202 · Cited by 12
“…and substance P have been reported [Rossor et al., 1980b; Crystal and Davies, 19821, but brain concentrations of cholecystokinin, enkephalins, neurotensin, thyrotropinreleasing hormone, and vasoactive intestinal polypeptide are unaltered in AD [see Davies et al., 1980; Hardy et al., 19851.”
Characteristics of [D-Trp8]-somatostatin-sensitive B50 phosphorylation
Dokas, L. A., Klis, M., Liauw, A., & Coy, D. H. (1985) · Peptides · doi:10.1016/0196-9781(85)90434-6 · Cited by 8
Neurochemistry: Peptides and Alzheimer's disease
Fine, A. (1986) · Nature · doi:10.1038/319537a0 · Cited by 9
TETRAHYDROAMINOACRIDINE AND ALZHEIMER'S DISEASE
Katona, C., O'Brien, C., Tyrrell, P. J., Hardy, J., Rossor, M. N., & Walshe, J. M. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90142-5 · Cited by 8
Molecular signatures of regional vulnerability to tauopathy in excitatory cortical neurons
Broekaart, D. W. M., Sharma, A., Ramakrishnan, A., Chongtham, A., Günther, D. M., Subramaniyan, S., Wang, M., Patel, V., Zhang, B., Grinberg, L. T., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02879-2 · Cited by 11
“Several studies have shown a dysfunctional inhibitory network in AD, with decreased expression of GABA in the neocortex and in cerebrospinal fluid, along with a loss of somatostatin-expressing interneurons [22, 32, 59, 80].”
CXCL12 Regulates the Cholinergic Locus and CHT1 Through Akt Signaling Pathway
Yan, J., Zhao, W., Guo, M., Han, X., & Feng, Z. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000453155 · Cited by 8
The human brain somatostatin interactome: SST binds selectively to P-type family ATPases
Solarski, M., Williams, D., Mehrabian, M., Wang, H., Wille, H., & Schmitt‐Ulms, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217392 · Cited by 8
Transcriptome and Translatome Regulation of Pathogenesis in Alzheimer’s Disease Model Mice
Eastman, G., Sharlow, E. R., Lazo, J. S., Bloom, G. S., & Sotelo-Silveira, J. R. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215357 · Cited by 9
“Thesomatostatinreceptor5was downregulatedatboththetranscriptomeandtrans-latomelevel,consistentwiththedecreasedlevels reportedforthesereceptorsinthecortexofAD patients[108,109].”
Jinno, S., Araki, K., Matsumoto, Y., Suh, Y., & Yamamoto, T. (2008) · Brain Research · doi:10.1016/j.brainres.2008.10.052 · Cited by 8
Bogdanović, N., Nilsson, L. N. G., Adem, A., Winblad, B. G., & ̈m, L. B. (1993) · Brain Research · doi:10.1016/0006-8993(93)90934-f · Cited by 7
The neurobiology of aging and the neurobiology of depression: Is there a relationship?
Nemeroff, C. B. (1988) · Neurobiology of Aging · doi:10.1016/s0197-4580(88)80036-8 · Cited by 7
Cognitive Enhancers in Alzheimer’s Disease
Cutler, N. R., & Narang, P. K. (1986) · Springer eBooks · doi:10.1007/978-1-4684-1253-6_16 · Cited by 7
CLINICAL PERSPECTIVES ON NEUROPEPTIDES
Lewis, D. A., & Bloom, F. E. (1987) · Annual Review of Medicine · doi:10.1146/annurev.me.38.020187.001043 · Cited by 7
Somatostatin Alterations and Brain Diseases
Epelbaum, J., Agid, Y., Enjalbert, A., Hamon, M., Javoy-Agid, F., Kordon, C., Lamour, Y. A., & Moyse, E. (1985) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-7886-4_15 · Cited by 7
Neuropeptides in Alzheimer's Disease: Clinical implications
Mazurek, M. F., Beal, M. F., & Martin, J. B. (1986) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30946-0 · Cited by 8
Gulya, K., Watson, M., Vickroy, T. W., Roeske, W. R., Perry, R. H., Perry, E. K., DUCKLES, S. P., & Yamamura, H. I. (1986) · Advances in behavioral biology · doi:10.1007/978-1-4613-2179-8_13 · Cited by 7
Neuropathological processes in Alzheimer's disease
Price, D. L., Struble, R. G., Whitehouse, P. J., Kitt, C. A., & Cork, L. C. (1985) · Drug Development Research · doi:10.1002/ddr.430050106 · Cited by 8
“Recent studies indicate that somatostatinlike immunoreactivity is reduced in the cerebral cortex of patients with ADlSDAT [Davies et al., 1980; Rossor et al., 1980; Davies and Terry, 19811.”
BackgroundClinical pharmacology of senile dementia
Fisman, M. (1981) · Progress in Neuro-Psychopharmacology · doi:10.1016/0364-7722(81)90026-6 · Cited by 7
Cholinergic Neuropsychopharmacology and Neuropathology of Dementias
Retz, K. C., & Lal, H. (1985) · Springer eBooks · doi:10.1007/978-1-4684-1218-5_11 · Cited by 8
Recent Advances in the Neurochemical Pathology of Alzheimer's Disease
Nemeroff, C. B., Bissette, G., Slotkin, T. A., Seidler, F. J., Miller, B. E., & GHANBARI, H. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb00216.x · Cited by 7
“More than ten years ago Davies, Katzman, and Terry (1980) reported a marked reduction in the concentrations of SRIF, a tetradecapeptide, in the hippocampus and cerebral cortex of patients with AD.”
BackgroundDementia in Movement Disorders
Teräväinen, H., Hietanen, M., Stoessl, A. J., & Calne, D. B. (1986) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710003729x · Cited by 7
Travaglini, K. J., Gabitto, M. I., Ding, Y., Agrawal, A., Postupna, N. O., Mahoney, J. T., Kaplan, E. S., Melief, E. J., Goldy, J., Chakka, A. B., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.01.734821 · Cited by 9
Nagarajan, R., Zhang, H., Lyu, J., Kambali, M., Wang, M., & Rudolph, U. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70186 · Cited by 6
Joshi, A., Giorgi, F. M., & Sanna, P. P. (2024) · eNeuro · doi:10.1523/eneuro.0118-24.2024 · Cited by 8
“Neuropeptide SST and its downregulation have been associated with formation of A β plaques via upregulation of neprilysin-catalyzed proteolytic degradation (P. Davies et al., 1980; Watamura et al., 2021).”
BackgroundPabba, M., & Sibille, E. L. (2015) · Advances in biological psychiatry · doi:10.1159/000434736 · Cited by 7
Jeeps, C. M., SILCOX, A. A., Lloyd, B. B., & Clayton, B. E. (1986) · Journal of Clinical Pathology · doi:10.1136/jcp.39.2.199 · Cited by 6
Postmortem Studies in Psychiatry
Bracha, H. S., & Kleinman, J. E. (1984) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30745-7 · Cited by 6
Metadata
- Authors
- Davies, P., Katzman, R., & Terry, R. D.
- Affiliations
- Albert Einstein College of Medicine (US)
- Venue
- Nature
- Published
- 1980-11
- Volume
- 288
- Issue
- 5788
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034969383
- Cited by
- 882
- References
- 9
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 20 · 2023: 18 · 2022: 11 · 2021: 11 · 2020: 19 · 2019: 8 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 9 · 2012: 8
- FWCI
- 25.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- Alzheimer's disease, senile dementia of the Alzheimer type, somatostatin, somatostatin-like immunoreactivity, cerebral cortex, neuropeptides, peptidergic neurons, neurotransmitter systems, cholinergic neurons, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Alzheimer Disease, Cerebral Cortex, Choline O-Acetyltransferase, Dementia, Humans, Middle Aged, Radioimmunoassay, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.